Textbook of Personalized Medicine - Second Edition [2015]

265 contain the MLL-AF4 or the BCR-ABL fusion are often candidates for allogeneic hematopoietic stem cell transplantation during ...

266 Pharmacogenetics of Cancer Chemotherapy Present clinical algorithms assign adjuvant chemotherapy according to prognosis, but ...

267 Thiopurine Methyltransferase Polymorphisms in the thiopurine methyltransferase (TPMT) gene have been convincingly associated ...

268 this inhibition slows down the tumor growth. Intravenously administered 5-FU is inactivated by dihydropyrimidine (DPD), an e ...

269 A case-control study of Japanese cancer patients revealed that those with the variant UGT1A1 alleles were at signifi cantly ...

270 Mathematical Modeling of Tumor Microenvironments The environment of a tumor is crucial determining factor in its development ...

271 coding genes specifi c to each breast cancer metastasis. The identifi ed signaling net- works for the three types of breast ...

272 Role of Splice Variants in Resistance to Cancer Therapy Alternative splicing is important for increasing the diversity of th ...

273 problematic as there is no ideal remedy for it. One compound, OC 144-093 (Ontogen Corporation, Carlsbad, California) has pas ...

274 of imatinib revealed that this targeted drug is most effective in controlling glucose transport, direct glucose oxidation fo ...

275 associated with lower disease control rate, shorter progression-free survival, and shorter overall survival. MET overexpress ...

276 A novel pyrido[2,3-d]pyrimidine derivative, PD180970, has been shown to potently inhibit Bcr-Abl and induce apoptosis in Bcr ...

277 pockets of residual disease quickly (Predina et al. 2013 ). These authors found that recurrent tumors and draining lymph nod ...

278 microenvironment were signifi cantly different from those in myoblast containing matrices. Blocking breast cancer cell A3 ad ...

279 Bioinformatic Approach to Personalizing Treatment of GBM An example of bioinformatic approach to personalize treatment of GB ...

280 therapy for a given patient’s genetic alteration profi le. The parties will utilize M.D. Anderson’s clinical expertise to va ...

281 Genetics and Genomics of Brain Cancer Genetic alterations in GBM have been studied extensively using molecular diagnos- tic ...

282 infi ltrating, high-grade malignant glioma phenotype with prominent pathological and molecular resemblance to GBM in humans ...

283 (APVACs) tailored for each patient based on the individual aspects of the patient’s tumor and immune system. The latest tech ...

284 genetic landscape approach may be applied to other aggressive types of cancer, such as ovarian and lung cancer. Eventually, ...